Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar:46 Suppl 2:S141-S145.
doi: 10.1097/ICL.0000000000000650.

Imaging Biomarkers for Dry Eye Disease

Edoardo Villani  1 , Francesco Bonsignore, Elisa Cantalamessa, Massimiliano Serafino, Paolo Nucci
Affiliations
Review

Imaging Biomarkers for Dry Eye Disease

Edoardo Villani et al. Eye Contact Lens. 2020 Mar.

Abstract

The clinical, scientific, economic, and regulatory impact of validated biomarkers and surrogate endpoints has the potential to revolutionize the approach to ocular surface diseases. At present, there is a growing interest in developing biomarkers for dry eye disease, and other ocular surface disorders and imaging are of the most promising approaches to this issue. Among the several and constantly evolving imaging technologies, some tools that are aimed to assess tear film stability and volume, meibomian gland morphology and function, and ocular surface microanatomy are now supported by a good body of evidence. To date, clinical trials on ocular surface diseases have slowly started incorporating imaging biomarkers for disease diagnosis and stratification and as surrogate endpoints. Major efforts are still needed, mainly aimed to improve automatic acquisition and quantitative analysis, standardization (standard operating procedures, normative databases etc.), and validation of imaging biomarkers.

PubMed Disclaimer

References

    1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf 2017;15:276–283.
    1. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf 2017;15:539–574.
    1. Roy NS, Wei Y, Kuklinski E, et al. The growing need for validated biomarkers and endpoints for dry eye clinical research. Invest Ophthalmol Vis Sci 2017;58:BIO1–BIO19.
    1. Novack GD. Why aren't there more pharmacotherapies for dry eye? Ocul Surf 2014;12:227–230.
    1. Villani E, Massaro D, Scaramuzzi M, et al. Decade-long profile of imaging biomarker use in ophthalmic clinical trials. Invest Ophthalmol Vis Sci 2017;58:BIO76–BIO81.

MeSH terms

LinkOut - more resources